FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy

Cancer Research

Volumn 70, Issue 3, 2010, Pages 1090-1100

  McKeen, Hayley D ^a   Byrne, Christopher ^a   Jithesh, Puthen V ^a   Donley, Christopher ^a   Valentine, Andrea ^a   Yakkundi, Anita ^a   O'Rourke, Martin ^b,c   Swanton, Charles ^a   McCarthy, Helen O ^a   Hirst, David G ^a   Robson, Tracy ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FK 506 BINDING PROTEIN; FULVESTRANT; SERINE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CATHEPSIN D; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPHILINS; IMMUNOPRECIPITATION; KAPLAN-MEIERS ESTIMATE; META-ANALYSIS AS TOPIC; PHOSPHORYLATION; PROTEIN BINDING; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSFECTION;

EID: 76249098981     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2515     Document Type: Article

References (50)

1. Pietras RJ. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 2006;11:704-17.
2. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-52.
3. Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther 2002;24 Suppl C:C3-25.
4. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998;50:151-96.
5. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007;213:610-7.
6. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005;5: 343-57.
7. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
8. Oesterreich S, Zhang Q, Hopp T, et al. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 2000;14:369-81.
9. Wu L, Wu Y, Gathings B, et al. Smad4 as a transcription corepressor for estrogen receptor α. J Biol Chem 2003;278:15192-200.
10. Robson T, Joiner MC, Wilson GD, et al. A novel human stress response-related gene with a potential role in induced radioresistance. Radiat Res 1999;152:451-61.
11. Robson T, Price ME, Moore ML, et al. Increased repair and cell survival in cells treated with DIR1 antisense oligonucleotides: implications for induced radioresistance. Int J Radiat Biol 2000;76: 617-23.
12. Ratajczak T, Carrello A. Cyclophilin 40 (CyP-40), mapping of its hsp90 binding domain and evidence that FKBP52 competes with CyP-40 for hsp90 binding. J Biol Chem 1996;271:2961-5.
13. Jascur T, Brickner H, Salles-Passador I, et al. Regulation of p21 (WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell 2005;17:237-49.
14. Li YY, Liu LQ, Yang J, et al. Effect of WISp39 on proliferation, cell cycle and apoptosis of U937 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007;15:733-7.
15. McKeen HD, McAlpine K, Valentine A, et al. A novel FK506-like binding protein interacts with the glucocorticoid receptor and regulates steroid receptor signaling. Endocrinology 2008;149:5724-34.
16. Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein. Endocr Rev 1997;18:306-60.
17. Ward BK, Mark PJ, Ingram DM, Minchin RF, Ratajczak T. Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat 1999;58: 267-80.
18. Kumar P, Mark PJ, Ward BK, Minchin RF, Ratajczak T. Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001;284:219-25.
19. Ostrow KL, Park HL, Hoque MO, et al. Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res 2009;15:1184-91.
20. Gougelet A, Bouclier C, Marsaud V, et al. Estrogen receptor α and β subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J Steroid Biochem Mol Biol 2005;94:71-81.
21. Knoblauch R, Garabedian MJ. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol Cell Biol 1999; 19:3748-59.
22. Oxelmark E, Roth JM, Brooks PC, Braunstein SE, Schneider RJ, Garabedian MJ. The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion. Mol Cell Biol 2006;26:5205-13.
23. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Lett 2007;256:1-24.
24. Iorns E, Turner NC, Elliott R, et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008;13:91-104.
25. Wen J, Li R, Lu Y, Shupnik MA, et al. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 2009;28:575-86.
26. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14.
27. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
28. Loi S, Haibe-Kains B, Desmedt C, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
29. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
30. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
31. Vega VB, Lin CY, Lai KS, et al. Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding sites. Genome Biol 2006;7:R82.
32. Abukhdeir AM, Vitolo MI, Argani P, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A 2008;105:288-93.
33. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 1984;114:629-37.
34. Nardulli AM, Katzenellenbogen BS. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Endocrinology 1986;119:2038-46.
35. Tateishi Y, Kawabe Y, Chiba T, et al. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 2004;23:4813-23.
36. Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α. Mol Endocrinol 2005;19:2901-14.
37. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999;19:4535-45.
38. Golden T, Aragon IV, Zhou G, Cooper SR, Dean NM, Honkanen RE. Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Cancer Lett 2004;215:95-100.
39. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006;281:9837-40.
40. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 2006;103:5923-5928.
41. Han W, Han MR, Kang JJ, et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006;6:92.
42. Kuske B, Naughton C, Moore K, et al. Endocrine therapy resistance can be associated with high estrogen receptor α (ERα) expression and reduced ERα phosphorylation in breast cancer models. Endocr Relat Cancer 2006;13:1121-33.
43. Gaci Z, Bouin-Pineau MH, Gaci M, Daban A, Ingrand P, Metaye T. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol 2001;18:793-800.
44. Rodriguez J, Vazquez J, Corte MD, et al. Clinical significance of cathepsin D concentration in tumor cytosol of primary breast cancer. Int J Biol Markers 2005;20:103-11.
45. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000;97:9042-6.
46. Mukherjee S, Conrad SE. c-myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005;280:17617-25.
47. Britton DJ, Hutcheson IR, Knowlden JM, et al. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 2006;96:131-46.
48. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83.
49. Sarwar N, Kim JS, Jiang J, et al. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression. Endocr Relat Cancer 2006;13:851-61.
50. Murphy LC, Niu Y, Snell L, Watson P. Phospho-serine-118 estrogen receptor-α expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 2004;10: 5902-6.